The Latest in CLL

CLL: The initial work-up

November 13, 2018

Variant not linked to CLL in Southeast Europe

November 7, 2018

Sandoz halts pursuit of U.S. approval for rituximab biosimilar

November 5, 2018

Ibrutinib discontinuation harms survival in CLL

October 18, 2018

Ibrutinib plus obinutuzumab gets priority review in CLL/SLL

October 17, 2018

Some mutation testing can be useful at CLL diagnosis

October 5, 2018

Novel options for treating hairy cell leukemia

October 2, 2018

Real-world clues for optimal sequencing of CLL novel agents

September 25, 2018

FDA approves new drug for CLL/SLL and follicular lymphoma

September 25, 2018

FDA approves new hairy cell leukemia drug

September 13, 2018

CLL

Venetoclax label now includes MRD data

September 12, 2018

RESONATE-2 update: First-line ibrutinib has sustained efficacy in older CLL patients

September 6, 2018

Combo treatment yields MRD-negative remissions in CLL

August 23, 2018

Caution urged over real-world bleeding risk with ibrutinib

August 14, 2018

New chronic lymphocytic leukemia guidelines from the UK

August 8, 2018